|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Subvoxel light-sheet microscopy for high-resolution high-throughput volumetric imaging of large biomedical specimens显示文摘A key challenge when imaging whole biomedical specimens is how to quickly obtain massive cellular information over a large field of view(FOV).We report a subvoxel light-sheet microscopy(SLSM)method enabling high-throughput volumetric imaging of mesoscale specimens at cellular resolution.A nonaxial,continuous scanning strategy is developed to rapidly acquire a stack of large-FOV images with three-dimensional(3-D)nanoscale shifts encoded.Then,by adopting a subvoxel-resolving procedure,the SLSM method models these low-resolution,cross-correlated images in the spatial domain and can iteratively recover a 3-D image with improved resolution throughout the sample.This technique can surpass the optical limit of a conventional light-sheet microscope by more than three times,with high acquisition speeds of gigavoxels per minute.By fast reconstruction of 3-D cultured cells,intact organs,and live embryos,SLSM method presents a convenient way to circumvent the trade-off between mapping large-scale tissue(>100 mm3)and observing single cell(∼1-μm resolution).It also eliminates the need of complicated mechanical stitching or modulated illumination,using a simple light-sheet setup and fast graphics processing unit-based computation to achieve high-throughput,high-resolution 3-D microscopy,which could be tailored for a wide range of biomedical applications in pathology,histology,neuroscience,etc. | Peng Fei Jun Nie Juhyun Lee Yichen Ding Shuoran Li Hao Zhang Masaya Hagiwara Tingting Yu Tatiana Segura Chih-Ming Ho Dan Zhu Tzung KHsiaic | 2019 | Advanced Photonics2019，1，1： | 6 |
| 2 | Association of serum phospholipid PUFAs with cardiometabolic risk: Beneficial effect of DHA on the suppression of vascular proliferation/inflammation显示文摘 | Juhyun Song Nayeon Kwon Mi-Hyang Lee Young-Guk Ko Jong Ho Lee Oh Yoen Kim | 2014 | Clinical Biochemistry2014，，： | 1 |
| 3 | DDoS Attack Detection Method Using Cluster Analysis显示文摘 | Kenusoo Lee Juhyun Kim | 2008 | ScienceDirect2008，1，34： | 1 |
| 4 | Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus显示文摘 | Keun-Hwa Jung Kon Chu Soon-Tae Lee Juhyun Kim Dong-In Sinn Jeong-Min Kim Dong-Kyu Park Jung-Ju Lee Seung U. Kim Manho Kim Sang Kun Lee Jae-Kyu Roh | 2006 | Neurobiology of Disease2006，，2： | 1 |
| 5 | DEloS attack detection method using cluster analysis显示文摘 | LEE K JUHYUN K KI H K | 2008 | Expert Systems with Applications2008，34，3： | 1 |
| 6 | DDoS attack detection method using cluster analysis显示文摘 | Keunsoo Lee Juhyun Kim Ki Hoon Kwon Younggoo Han Sehun Kim | 2007 | Expert Systems With Applications2007，，3： | 1 |
| 7 | Microstructural, electrical properties and temperature stability of resonant frequency in Pb(Ni1/2W1/2)-Pb(Mn1/3Nb2/3)O3-Pb(Zr,Ti)O3 ceramics for high-power piezoelectric transformer显示文摘 | Yoo Juhyun Lee Yongwoo Yoon Kwanghee | 2001 | Jpn J Appl Phys2001，40，： | 1 |
| 8 | DDoS attack detection method using cluster analysis 显示文摘 | Keunsoo Lee Juhyun Kim Ki Hoon Kwon Younggoo Han Sehun Kim | 2008 | Expert Systems with Applications2008，34，3： | 1 |
| 9 | The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction显示文摘We aimed to determine whether combination of LIM-kinase 2 inhibitor(LIMK2i)and phosphodiesterase type-5 inhibitor(PDE5i)could restore erectile function through suppressing cavernous fibrosis and improving caver nous apoptosis in a rat model of cavernous nerve crush injury(CNCI).Seventy 12-week-old Sprague-Dawley rats were equally distributed into five groups as follows:(1)sham surgery(Group S),(2)CNCI(Group I),(3)CNCI treated with daily intraperitoneal administration of 10.0 mg kg^-1 LIMK2i(Group I+L),(4)daily oral administration of 20.0 mg kg-1 udenafil,PDE5i(Group I+U),and(5)combined administration of 10.0 mg kg^-1 LIMK2i and 20.0 mg kg^-1 udenafil(Group I+L+U).Rats in Groups I+L,I+U,and I+L+U were treated with respective regimens for 2 weeks after CNCI.At 2 weeks after surgery,erectile response was assessed using electrostimulation.Penile tissues were processed for histological studies and western blot.Group I showed lower intracavernous pressure(ICP)/mean arterial pressure(MAP),lower area under the curve(AUC)/MAP,decreased immunohistochemical staining for alpha-smooth muscle(SM)actin,higher apoptotic index,lower SM/collagen ratio,increased phospho-LIMK2-positive fibroblasts,decreased protein kinase B/endothelial nitric oxide synthase(Akt/eNOS)phosphorylation,increased LIMK2/cofilin phosphorylation,and increased protein expression of fibronectin,compared to Group S.In all three treatment groups,erectile responses,protein expression of fibronectin,and SM/collagen ratio were improved.Group I+L+U showed greater improvement in erectile response than Group I+L.SM content and apoptotic index in Groups I+U and I+L+U were improved compared to those in Group I.However,Group I+L did not show a significant improvement in SM content or apoptotic index.The number of phospho-LIMK2-positive fibroblasts was normalized in Groups I+L and I+L+U,but not in Group I+U.Akt/eNOS phosphorylation was improved in Groups I+U and I+L+U,but not in Group I+L.LIMK2/cofilin phosphorylation was improved in Groups I+L and I+L+U,but not in Group I+U.Our data indicate that combined treatment of LIMK2i and PDE5i immediate after CN injury could improve erectile function by improving cavernous apoptosis or eNOS phosphorylation and suppressing cavernous fibrosis.Rectification of Akt/eNOS and LIMK2/cofilin pathways appears to be involved in their improvement. | Min Chui Cho Junghoon Lee Juhyun Park Sohee Oh Ji Sun Chai Hwancheol Son Jae-Seung Paick Soo Woong Kim | 2019 | Asian Journal of Andrology2019，21，5： | 1 |
| 10 | Microstruetural and piezoelectric properties of low temperature sintering PMN - PZT ceramics with the amount of Li2CO3 addition 显示文摘 | Juhyun Yoo Changbae Lee Yeongho Jeong | 2005 | Mater Chem Phys2005，90，： | 1 |
| 11 | Apoptosis signal regulating kinase 1 (ASK1):potential as a therapeutic target for Alzheimer's disease 显示文摘 | Song Juhyun Kyung Ah Park Won Taek Lee | 2014 | Int J Mol Sci2014，15，2： | 1 |
| 12 | Vaccinia-related kinase 2 variants differentially affect breast cancer growth by regulating kinase activity显示文摘Genetic information is transcribed from genomic DNA to mRNA,which is then translated into threedimensional proteins.mRNAs can undergo various post-transcriptional modifications,including RNA editing that alters mRNA sequences,ultimately affecting protein function.In this study,RNA editing was identified at the 499th base(c.499)of human vaccinia-related kinase 2(VRK2).This RNA editing changes the amino acid in the catalytic domain of VRK2 from isoleucine(with adenine base)to valine(with guanine base).Isoleucine-containing VRK2 has higher kinase activity than the valine-containing VRK2,which leads to an increase in tumor cell proliferation.Earlier we reported that VRK2 directly interacts with dystrobrevin-binding protein(dysbindin)and results in reducing its stability.Herein,we demonstrate that isoleucine-containing VRK2 decreases the level of dysbindin than valinecontaining VRK2.Dysbindin interacts with cyclin D and thereby regulates its expression and function.The reduction in the level of dysbindin by isoleucine-containing VRK2 further enhances the cyclin D expression,resulting in increased tumor growth and reduction in survival rates.It has also been observed that in patient samples,VRK2 level was elevated in breast cancer tissue compared to normal breast tissue.Additionally,the isoleucine form of VRK2 exhibited a greater increase in breast cancer tissue.Therefore,it is concluded that VRK2,especially dependent on the 167th variant amino acid,can be one of the indexes of tumor progression and proliferation. | SEUNG-HEE GWAK JUHYUN LEE EUNJI OH DOHYUN LEE WONSHIK HAN JONGMIN KIM KYONG-TAI KIM | 2024 | Oncology Research2024，32，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员